SuperworthDexCom DXCM
- Market cap
- $29.4B
- PE
- 30.9×
- 8y median 102×
- Forward PE
- 27.7×
- 10y median 102×
- Price to sales
- 5.9×
- EV/EBIT
- 25.3×
- Revenue, 12 months
- $5B
- +16% on a year ago
- Net margin
- 20.1%
- Free cash flow yield
- 4.8%
DexCom trades at 30.9× trailing earnings, cheaper than 96% of the last ten years. Revenue was $5B over the last twelve months, up 16% on a year earlier with a 20% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $975M+27% | $1B+27% | $921M+24% | $1B+15% | $994.2M+2% | $1.1B+8% | $1B+13% | $1.2B+15% | $1.2B+22% | $1.3B+13% | $1.2B+15% | $1.3B+13% | |
| Cost of revenue | $351.7M+28% | $377.9M+38% | $359.1M+29% | $377.6M+16% | $400.4M+14% | $457.7M+21% | $447M+25% | $468.3M+24% | $477.9M+19% | $466.9M+2% | $441.6M−1% | $478.4M+2% |
| Gross profit | $623.3M+26% | $656.6M+21% | $561.9M+22% | $626.7M+15% | $593.8M−5% | $655.8M−0% | $589M+5% | $688.8M+10% | $731.4M+23% | $792.7M+21% | $750.3M+27% | $830M+21% |
| R&D | $131.4M+19% | $136.1M+17% | $141.5M+19% | $136M+14% | $135.4M+3% | $139.5M+3% | $145.2M+3% | $148.2M+9% | $157.5M+16% | $148.2M+6% | $145.3M+0% | $153M+3% |
| SG&A | $286.4M+22% | $303.6M−1% | $319.3M+8% | $332.7M+11% | $306.4M+7% | $327.4M+8% | $310.1M−3% | $328M−1% | $331.4M+8% | $321.5M−2% | $349.7M+13% | $358.7M+9% |
| $205.5M+39% | $216.9M+73% | $101.1M+114% | $158M+23% | $152M−26% | $188.9M−13% | $133.7M+32% | $212.6M+35% | $242.5M+60% | $323M+71% | $255.3M+91% | $318.3M+50% | |
| Interest expense | $4.9M+7% | $4.9M+4% | $4.6M+0% | $4.8M−19% | $4.7M−4% | $4.9M+0% | $4.7M+2% | $4.7M−2% | $4.7M+0% | $4.2M−14% | $3.1M−34% | $3M−36% |
| Pre-tax income | $240.4M+64% | $246.2M+85% | $132.5M+105% | $187.8M+18% | $177.4M−26% | $211.3M−14% | $154.3M+17% | $241.1M+28% | $352.3M+99% | $340.7M+61% | $269.5M+75% | $317.5M+32% |
| $119.7M+166% | −$10.1M | −$13.9M | $44.3M+2% | $42.8M−64% | $59.6M | $48.9M | $61.3M+38% | $68.5M+60% | $73.4M+23% | $70M+43% | $68.4M+12% | |
| Net income | $120.7M+19% | $256.3M+179% | $146.4M+201% | $143.5M+24% | $134.6M+12% | $151.7M−41% | $105.4M−28% | $179.8M+25% | $283.8M+111% | $267.3M+76% | $199.5M+89% | $249.1M+39% |
| $0.29+21% | $0.61+177% | $0.36+200% | $0.35+25% | $0.34+17% | $0.37−39% | $0.27−25% | $0.45+29% | $0.70+106% | $0.67+81% | $0.51+89% | $0.64+42% | |
| 426.8M+0% | 417.2M−2% | 416.7M−0% | 416.8M−3% | 410.2M−4% | 406.7M−3% | 407.5M−2% | 408.2M−2% | 407.4M−1% | 399M−2% | 393.6M−3% | 390.1M−4% |
EPS, diluted: 14 periods, Q4 FY14 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 6 periods, Q4 FY12 to Q4 FY21: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. 8 periods, Q4 FY14 to Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Estimates
Next earnings report: .
| Quarter | Revenue | Range | EPS | Range | Analysts |
|---|---|---|---|---|---|
| Q3 FY26 | $1.3B | $1.3B to $1.3B | $0.67 | $0.64 to $0.71 | 16 |
| Q4 FY26 | $1.4B | $1.4B to $1.4B | $0.73 | $0.69 to $0.76 | 15 |
| Q1 FY27 | $1.3B | $1.3B to $1.3B | $0.65 | $0.63 to $0.66 | 6 |
| Q2 FY27 | $1.4B | $1.4B to $1.5B | $0.77 | $0.75 to $0.78 | 6 |
| Q3 FY27 | $1.5B | $1.5B to $1.5B | $0.80 | $0.78 to $0.82 | 6 |
| Q4 FY27 | $1.5B | $1.5B to $1.6B | $0.88 | $0.86 to $0.90 | 6 |
| Q1 FY28 | $1.5B | $1.5B to $1.5B | $0.78 | $0.77 to $0.80 | 14 |
| Q2 FY28 | $1.6B | $1.6B to $1.6B | $0.89 | $0.87 to $0.90 | 14 |
Peers
Companies in Medical - Devices nearest DexCom's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| DXCMDexCom | $29.4B | 30.9× | 102× | 27.7× | 5.9× | +16% | 20.1% |
| GEHCGE HealthCare Technologies | $32.3B | 16.4× | 17.0× | 13.8× | 1.5× | +7% | 9.3% |
| ZBHZimmer Biomet | $18.8B | 24.0× | 31.4× | n/m | 2.2× | +9% | 9.5% |
| EWEdwards Lifesciences | $51.3B | 51.2× | 40.3× | 28.3× | 7.9× | +15% | 15.4% |
| BSXBoston Scientific | $66.2B | 18.5× | 67.0× | 14.1× | 3.2× | +14% | 17.5% |
| SYKStryker | $117.8B | 31.8× | 41.2× | 19.3× | 4.6× | +8% | 14.4% |
| MDTMedtronic | $122B | 23.4× | 28.2× | 15.9× | 3.3× | +10% | 13.9% |
| ABTAbbott Laboratories | $179.4B | 38.7× | 36.7× | 17.7× | n/m | n/m | n/m |
| LIVNLivaNova | $4.5B | 23.9× | 72.5× | n/m | 3.0× | +12% | 12.8% |
| ITGRInteger | $4.3B | 34.6× | 33.5× | n/m | 2.3× | +3% | 7.0% |
| Peer median | $51.3B | 24.0× | 36.7× | 16.8× | 3.1× | +9% | 13.4% |
Investors who own it
Investors we follow who held DexCom at the end of Jun 30, 2026, from their 13F filings.
- Baillie GiffordBaillie Gifford0.9% of portfoliotrimmed
- Ron BaronBaron Capital0.0% of portfolioadded
More on DexCom
Each number over time
- PE ratio
- Forward PE
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
- #2of 17Medical device stocks with the highest profit margins
- #2of 12Medical device stocks with the fastest earnings growth
- #5of 17Medical device stocks with the fastest revenue growth
- #6of 13Medical device stocks with the highest free cash flow yield
- #9of 13Medical device stocks with the lowest PE ratio
- #10of 13Medical device stocks with the lowest EV/EBIT
Its groups
About
- Industry
- Medical - Devices
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .